Legal & General Group Plc Invests $35.34 Million in Smith & Nephew SNATS, Inc. $SNN

Legal & General Group Plc bought a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 563,432 shares of the medical equipment provider’s stock, valued at approximately $35,338,000.

Several other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Smith & Nephew SNATS during the second quarter worth $505,323,000. River Road Asset Management LLC grew its stake in Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Smith & Nephew SNATS by 5.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after acquiring an additional 100,697 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Smith & Nephew SNATS during the second quarter worth $89,325,000. Finally, Dimensional Fund Advisors LP increased its position in Smith & Nephew SNATS by 44.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock valued at $33,436,000 after acquiring an additional 324,080 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Morgan Stanley reissued an “overweight” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research note on Monday, August 24th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Sanford C. Bernstein set a $31.85 price objective on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Finally, Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $29.01 on Friday. The firm has a 50 day moving average price of $30.22 and a 200 day moving average price of $31.68. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79.

Smith & Nephew SNATS Announces Dividend

The company also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be given a dividend of $0.312 per share. This represents a dividend yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.